Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADVM vs BIIB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: ADVM 0 – 6 BIIB Matrix Metrics: ADVM 2 – 8 BIIB

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Adverum Biotechnologies, Inc. (ADVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADVM carries a Unified Composite Score of 62.4/100 (BUY) at $4.36 (N/M Forward P/E, 0.0% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin).

  • Composite vs. Pillar Nuance: While ADVM currently prints a higher short-term Unified Composite Score (62.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 0.0% operating margin) and revenue trajectory (+10.6% vs. -70.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADVM vs BIIB
ADVM NASDAQ
Adverum Biotechnologies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.36
+4.06% 1D
Market Cap $91.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.04β · 17% Vol
Unified Composite Score
62.4 / 100 BUY
Tech 60.0 Fund 57.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $4.21 · SMA50: $4.41
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03

6-Pillar Scorecard Institutional Category Breakdown (ADVM 0 – 6 BIIB)

Columns: Metric · ADVM · BIIB
1. Valuation Multiples BIIB
Forward P/E N/M 15.6x
Trailing P/E N/M 109.9x
PEG Ratio N/M 3.45x
EV / Revenue N/M 4.2x
2. Growth & Scale BIIB
Revenue Growth (YoY) -70.0% +10.6%
Earnings Growth (YoY) +0.0% -84.8%
TTM Revenue (USD) N/A $10.3B
Market Cap $91.8M $37.0B
3. Profitability & Quality BIIB
Gross Margin N/A 75.8%
Operating Margin 0.0% 23.5%
Net Profit Margin 0.0% 3.4%
Return on Equity (ROE) -417.8% 1.9%
4. Balance Sheet & Cash Flow BIIB
Cash Generation (TTM) N/A $1.64B
Cash Flow Margin N/A 16.0%
Net Cash / Leverage -417.8% ROE $6.50B Net Debt (0.41x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 30.2% (10th %ile) 18.4% (6th %ile)
Put/Call OI Skew N/A 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat BIIB
OpEx & R&D Intensity N/A 52.3% of Rev ($5.39B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biological Products, (No Disgnostic Substances) Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADVM (2) vs BIIB (8)
Institutional Metric ADVM BIIB Criterion Row Edge
Market Capitalization
Scale
$91.8M $37.0B Larger Scale BIIB
Trailing P/E Ratio
Valuation
N/M 109.9x Lower Multiple BIIB
Forward P/E Ratio
Valuation
N/M 15.6x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
-70.0% +10.6% Higher Growth BIIB
Operating Margin (TTM)
Profitability
0.0% 23.5% Higher Margin BIIB
Net Profit Margin
Profitability
0.0% 3.4% Higher Margin BIIB
Return on Equity (ROE)
Capital Efficiency
-417.8% 1.9% Higher ROE BIIB
52-Week Range Position
Momentum
55% ($2–$6) 92% ($160–$261) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
1.04β · 17% Vol 0.27β · 36% Vol Lower Realized Risk ADVM
Unified Institutional Score
Composite Signal
62.4 / 100 (BUY) 50.2 / 100 (HOLD) Higher Composite ADVM
Trailing 12M Revenue (USD)
Operating Scale
N/A $10.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.45x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (-417.8% ROE) $1.64B ($6.50B Net Debt (0.41x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +7.19 pp
ADVM: +2.35% · BIIB: +9.54%
3M Horizon BIIB +7.19 pp
ADVM: +2.35% · BIIB: +9.54%
6M Horizon BIIB +7.19 pp
ADVM: +2.35% · BIIB: +9.54%
1Y Horizon BIIB +7.19 pp
ADVM: +2.35% · BIIB: +9.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADVM vs BIIB. Trailing 12-month operating profitability (ADVM 0.0% vs BIIB 23.5%) and valuation multiples (ADVM N/M vs BIIB 15.6x Forward P/E) are benchmarked directly in Pillar 4 below.

ADVM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-417.8% · N/M
BIIB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10.3B
Gross Margin75.8%
Op. Margin23.5%
ROE / Fwd P/E1.9% · 15.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADVM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.2%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADVM Moat Profile Cyclical / Execution-Driven Positioning
Biological Products, (No Disgnostic Substances) Operator
Competes within the Biological Products, (No Disgnostic Substances) value chain with $91.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published

Investor FAQ ADVM vs BIIB Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Adverum Biotechnologies, Inc. (ADVM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADVM carries a Unified Composite Score of 62.4/100 (BUY) at $4.36 (N/M Forward P/E, 0.0% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin). Composite vs. Pillar Nuance: While ADVM currently prints a higher short-term Unified Composite Score (62.4/100 BUY vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 0.0% operating margin) and revenue trajectory (+10.6% vs. -70.0% YoY).

BIIB leads the Growth & Scale pillar: ADVM posts -70.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BIIB at +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin). On trailing 12-month operating scale, ADVM generates N/A in USD-normalized revenue versus $10.3B for BIIB. In operating R&D and SG&A reinvestment, ADVM deploys N/A (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($5.39B) (0 disclosures) for BIIB.

BIIB screens cheaper on headline valuation multiples. ADVM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADVM (-417.8% ROE) versus BIIB (1.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ADVM carries 30.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 17% Vol realized risk). By comparison, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.